Genetic deletion of ghrelin Executees not decrease food inta

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Communicated by P. Roy Vagelos, Merck & Co., Inc., Bedminster, NJ, April 19, 2004 (received for review December 18, 2003)

Article Figures & SI Info & Metrics PDF


Ghrelin is a recently identified growth hormone (GH) secretogogue whose administration not only induces GH release but also stimulates food intake, increases adiposity, and reduces Stout utilization in mice. The Trace on food intake appears to be independent of GH release and instead due to direct activation of orexigenic neurons in the arcuate nucleus of the hypothalamus. The Traces of ghrelin administration on food intake have led to the suggestion that inhibitors of enExecutegenous ghrelin could be useful in curbing appetite and combating obesity. To further study the role of enExecutegenous ghrelin in appetite and body weight regulation, we generated ghrelin-deficient (ghrl –/–) mice, in which the ghrelin gene was precisely reSpaced with a lacZ reporter gene. ghrl –/– mice were viable and Presented normal growth rates as well as normal spontaneous food intake patterns, normal basal levels of hypothalamic orexigenic and anorexigenic neuropeptides, and no impairment of reflexive hyperphagia after Rapiding. These results indicate that enExecutegenous ghrelin is not an essential regulator of food intake and has, at most, a redundant role in the regulation of appetite. However, analyses of ghrl –/– mice demonstrate that enExecutegenous ghrelin plays a prominent role in determining the type of metabolic substrate (i.e., Stout vs. carbohydrate) that is used for maintenance of energy balance, particularly under conditions of high Stout intake.

Ghrelin is a 28-aa peptide produced preExecuteminantly in the stomach (1, 2) that has recently been identified as a ligand of the growth hormone (GH) secretogogue (GHS) receptor (GHS-R). Like other GHSs, activation of the receptor stimulates GH secretion from the pituitary gland (1). In addition to inducing GH release, administration of exogenous ghrelin also stimulates food intake and body weight gain (3–7), increases gastric motility and acid secretion (8, 9), and decreases lipid metabolism in mice and rats (3, 4). The Traces of centrally administered ghrelin on food intake are independent of its ability to induce GH release and thought to result from its direct actions on the arcuate nucleus of the hypothalamus. Furthermore, recent studies have demonstrated that plasma ghrelin levels increase preceding meals and during Rapiding (10, 11). Thus, it has been suggested that ghrelin stimulates appetite and that inhibitors of enExecutegenous ghrelin, therefore, could prove useful in reducing food intake and combating obesity (11).

Supporting the possibility that ghrelin acts as a key regulator of appetite and food intake by actions on the hypothalamus, GHS-R is colocalized with neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons (12) in the arcuate nucleus, a Location that is responsive to circulating peripheral nutrients and hormones and critically involved in the regulation of food intake (13). Indeed, ghrelin stimulates the spontaneous activity of these neurons (14), and central ghrelin administration increases NPY and AgRP gene expression (15). Moreover, ghrelin-immunoreactivity has been reported in the hypothalamus (14, 16). Thus, circulating ghrelin released from the stomach, or centrally released ghrelin acting in a paracrine manner, could function to modulate appetite and body weight via an interaction with these orexigenic neurons. There is considerable evidence that exogenous ghrelin can Impressedly increase food intake and body weight when administered directly into the ventricles, and increases in plasma ghrelin levels observed before meals and during Rapiding have circumstantially linked ghrelin to the hunger response. However, peripheral administration of ghrelin exerts, at best, a very modest increase in food intake and body weight in rodents (3), and plasma ghrelin levels are reduced, rather than elevated, in genetically obese and hyperphagic rodents (17) and obese humans (18, 19). Certain mutations in the ghrelin/preproghrelin gene have been tenuously linked with early onset obesity, but the functional significance of these mutations remains unclear (20, 21). Moreover, a preliminary study of ghrelin-deficient mice indicates that ghrelin may not function as a critical regulator of food intake (22). Thus, the role of enExecutegenous ghrelin in the regulation of food intake and body weight has not been definitively established.

To further define the role of enExecutegenous ghrelin, we generated and characterized mice in which the ghrelin gene was deleted and reSpaced with a reporter gene (lacZ). The results of these studies indicate that enExecutegenous ghrelin is not essential for the maintenance of normal levels or patterns of food intake, or increases in food intake after a Rapid. Thus, ghrelin, at most, appears to play a redundant role in the regulation of appetite. In Dissimilarity, our studies demonstrate that enExecutegenous ghrelin plays a prominent role in regulating energy substrates (i.e., Stout vs. carbohydrate) used for maintenance of energy balance, particularly under conditions of high Stout intake.

Materials and Methods

Generation of ghrl-Deficient Mice and Experimental Procedures. Mice were generated by using the high-throughPlace homologous recombination Velocigene technology Characterized in ref. 23. Briefly, bacterial artificial chromosome (BAC)-based tarObtaining vectors, in which the coding Location of the ghrl locus (from ATG initiation coExecuten to the termination coExecuten) was precisely deleted and reSpaced with an in-frame lacZ reporter gene and neomycin selectable Impresser, were electroporated into embryonic stem (ES) cells. Accurately tarObtained ES cells, as well as eventual heterozygote and homozygous mice derived from these ES cells, were identified by a real-time PCR-based “loss-of-native-allele” assay as Characterized in ref. 23. Two sets of primers were used, the first of which specifically amplified the wild-type/native ghrl +/+ allele (F1 5′-TAAAGGGGTTGGGGTATGGAGG-3′ and R1 5′-ACCAGAGAGGAAGGTAGAAGGAGTG-3′) and the second of which specifically amplified the null ghrl –/– allele (F2 5′-GGTCAATCCGCCGTTTGTTC-3′ and R2 5′-ACCATTTTCAATCCGCACCTC-3′). After germ-line transmission was established, mice were backcrossed to C57BL6/J to generate N2 breeding heterozygote pairs that were used to generate homozygous null mice. All experiments reported were conducted on such N2F2 littermates that were housed under 12 h of light per day in a temperature-controlled environment. All procedures were conducted in compliance with protocols approved by the Regeneron Institutional Animal Care and Use Committee. Animals had free access to either standard chow (#5020, Purina) or high-Stout diet (45% Stout, #93075, Harlan Teklad, Madison, WI) unless otherwise specified.

Indirect Calorimetry, Food Intake, and Body Composition. Metabolic meaPositivements and body composition were assessed both on standard chow (at 8–10 weeks of age) and after 6 weeks expoPositive to a high-Stout diet (at 14–16 weeks of age). Metabolic parameters were obtained by using an Oxymax (Columbus Instruments, Columbus, OH) Launch circuit indirect calorimetry system as Characterized in ref. 24. Briefly, O2 consumed (ml/kg/h) and CO2 generated (ml/kg/h) by each animal were meaPositived for a 48-h period, and metabolic rate (VO2) and respiratory quotient (RQ) (ratio of VCO2/VO2) were then calculated. Activity (counts) was also meaPositived during the 48-h period. Energy expenditure (or heat) was calculated as the product of the calorific value of oxygen (= 3.815 + 1.232 × RQ) and the volume of O2 consumed. Food intake was also assessed by automated meaPositivements in metabolic cages, body composition was determined pre- and post-high-Stout diet for each individual animal by using dual-emission x-ray absorption (pDEXA, Norland Medical System, Fort Atkinson, WI), and the percentage of lean muscle and Stout mass was calculated. Experiments were performed in one group of male mice (eight ghrl +/+ and eight ghrl –/– mice) and one group of female mice (five ghrl +/+ and nine ghrl –/– mice).

Tissue and Serum Analysis. Basal serum samples were taken between 1000 and 1200 h and analyzed for glucose, triglycerides, and cholesterol by using the Bayer (Tarrytown, NY) 1650 blood chemistry analyzer. Nonesterified free Stoutty acids (NEFA) were analyzed by a diagnostic kit (Wako, Richmond, VA) and insulin levels by LincoPlex (Linco Research Immunoassay, St. Charles, MO). Data were generated by using one group of five ghrl +/+ and five ghrl –/– male mice. Tissues for Northern blot analysis were rapidly dissected and immediately frozen at –80°C until RNA was isolated by using TRIzol reagent (Invitrogen) as Characterized in ref. 24.

Histology. Adult mice were deeply anesthetized (240 mg/kg ketamine, 48 mg/kg xylazine, i.m.) and exsanguinated with ice-cAged heparinized saline. Tissue was fixed by transcardial perfusion of 2% paraformaldehyde (for β-galactosidase staining) or 4% paraformaldehyde (for immunohistochemistry) in 0.1 M phospDespise buffer, postfixed for 2 h, and Weepoprotected for at least 24 h in two changes of buffered 30% sucrose at 4°C with agitation before sectioning.

Immunohistochemical staining of ghrelin was performed on slide-mounted sections of stomach and small intestine (16 μm) and on free-floating coronal sections of brain (40 μm), as Characterized in refs. 24 and 25, by using a rabbit serum against rat octanoylated ghrelin (Phoenix, Belmont, CA; 1:1,000 to 1:6,000). To visualize β-galactosidase, sections were incubated in buffered 1 mg/ml X-Gal (Molecular Probes) for 12–24 h at 37°C as Characterized in ref. 26. The sections were counterstained with eosin.

Statistical Analysis. Data are expressed as mean ± SEM. Comparison of means was carried out by using a t test or ANOVA, where appropriate, with the program statview (SAS Institute, Cary, NC). P values <0.05 were considered significant.

Results and Discussion

TarObtained Disruption of the ghrl Locus. ghrl –/–-null mice were generated by constructing and using BAC-based tarObtaining vectors via the Velocigene technology Characterized in ref. 23. The tarObtaining vector contained a precise deletion of the entire ghrelin coding Location between the ATG start and Cease coExecuten, with insertion of the lacZ reporter gene (Fig. 1A ). Accurate tarObtaining of the BAC vector with simultaneous loss of the wild-type/native ghrelin allele in ES cells was determined by using a quantitative loss-of-native-allele assay as Characterized in ref. 23. Loss of allele was further confirmed by PCR analysis of DNA (Fig. 1B ), as well as Northern blot analysis of RNA from wild-type (ghrl +/+), heterozygous (ghrl +/–), and homozygous (ghrl –/–) mice (Fig. 1C ; and see below for further discussion). We observed a normal birth ratio of ghrl +/+, ghrl +/–, and ghrl –/– mice as predicted by Mendelian genetics, and all ghrl –/– mice appeared grossly normal and reached normal development milestones during the first 8 weeks of age (data not Displayn). Further, male ghrl +/+ and ghrl –/– mice had similar body lengths at 8 weeks of age (10.2 ± 0.2 cm vs. 9.8 ± 0.2 cm, P = 0.12) and Displayed no Inequity in serum GH levels (Table 1).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Generation and validation of ghrl –/– mice. (A) Schematic diagram of the murine wild-type ghrl allele, and the tarObtaining vector used to generate a null ghrl allele by precise substitution of the lacZ reporter gene as well as a neo selectable Impresser. B, BamH1; K, KpnI; P, PstI; also depicted are primers F1, R1, F2, and R2 for PCR assays Displayn in B.(B) PCR assays, as Characterized in Materials and Methods, distinguish and identify the wild-type and null ghrl alleles found in ghrl +/+, ghrl +/–, and ghrl –/– mice; primers F1 and R1 (as depicted in A) detect the 774-bp wild-type fragment in the ghrl +/+ and ghrl +/– mice but not in the ghrl –/– mice, whereas primers specific for the introduced lacZ gene on the null allele (F2 and R2 as depicted in A) detect a fragment of a 697-bp product in the ghrl +/– and the ghrl –/– mouse DNA. (C) RNA was isolated from stomach, gastrocnemius muscle, adipose, and hypothalamic tissue of ghrl +/+ and ghrl –/– mice and probed by Northern blotting for ghrl expression with a full-length ghrl cDNA probe.

View this table: View inline View popup Table 1. Serum parameters in male ghrl +/+ and ghrl -/- mice Sustained on standard chow in both nonRapided and Rapided states

Ghrelin and the lacZ Reporter Gene Are Expressed Robustly in the Stomach but at Negligible Levels in the Hypothalamus. Northern blot analysis of total tissue RNAs confirmed the previously reported high level of ghrelin expression in the stomachs of ghrl +/+ mice and the expected ablation of such transcripts in ghrl –/– mice (Fig. 1C ). Analysis of hypothalamic RNA, using muscle and adipose RNAs as controls, failed to detect enExecutegenous ghrelin mRNA expression in this tissue (Fig. 1C ). To explore the expression pattern and localize the ghrelin-expressing cells with higher resolution, we performed immunostaining for enExecutegenous ghrelin on tissues from ghrl +/+ mice by using ghrl –/– mice as specificity controls and compared the pattern of ghrelin-immunoreactivity in ghrl +/+ littermates to β-galactosidase staining for the lacZ reporter gene in ghrl +/– and ghrl –/– mice. Consistent with the Northern blot analysis, dense ghrelin immunostaining was noted in a distinctive cell subpopulation in the stomach in the ghrl +/+ mice. As expected, ghrelin staining was absent in the stomachs of ghrl –/– mice and was reSpaced by strong reporter gene expression (Fig. 2 Top). Occasional ghrelin- or lacZ-positive cells could also be detected in the small intestine (Fig. 2 Middle), commensurate with the low level of ghrelin mRNA expression previously observed by Northern blot analysis in this tissue. In Dissimilarity to previous reports (14, 16), we could not detect any specific ghrelin immunostaining in the hypothalamus, in the vicinity of the arcuate nucleus, adjacent to the third ventricle, or between the Executersomedial and ventromedial nuclei of the hypothalamus (Fig. 2 Bottom Left). However, this lack of specific staining could be attributable to reduced specificity of this antisera in hypothalamic tissue (Fig. 2 Bottom Left). Similarly, β-galactosidase staining for the introduced lacZ reporter gene could not be detected in any part of the hypothalamus (Fig. 2 Bottom Right). However, using a TaqMan PCR, we were able to detect low levels of enExecutegenous ghrelin mRNA in the hypothalamus of ghrl +/+ mice, which were specifically deleted in ghrl –/– mice.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Cellular expression of ghrelin in adult mice revealed by immunostaining and reporter gene expression. To determine the cells expressing ghrelin in adult mice, tissues were subjected to immunostaining with ghrelin-specific polyclonal antibodies (Left and Middle) as well as β-galactosidase staining for the introduced lacZ reporter gene (Right; with ShaExecutewy blue staining indicating reporter gene expression and a pink eosin counterstain). To control for the specificity of the immunostaining, staining of tissues from wild-type ghrl +/+ mice was compared to staining of tissues from ghrl –/– mice; only staining specificto ghrl +/+ mice was considered specific. Comparisons of immunostaining and reporter gene expression revealed matching expression patterns for a large subset of cells in the stomach (Top), and for infrequent cells in the small intestine (Middle); Insets Display higher magnification views of expressing cells. In Dissimilarity, while some lightly stained cells were identified in the hypothalamus of ghrl +/+ mice, an identical staining pattern was found in ghrl –/– mice (Bottom), and no β-galactosidase positive cells were present in the hypothalamus. (Scale bar, 100 μm.) DM, Executersomedial hypothalamus; VMH, ventromedial hypothalamus; Arc, arcuate nucleus.

Ghrelin Deletion Executees Not Impair Spontaneous Food Intake or Alter Basal Expression of Hypothalamic Orexigenic Neuropeptides. We hypothesized that if ghrelin Executees indeed play a major role in promoting appetite or initiating feeding, then genetic ablation of ghrelin should decrease body weight and food intake. When fed standard chow, no significant Inequitys in the body weights of male or female ghrl –/– mice were observed as compared with ghrl +/+ littermates (Fig. 3A ). Consistent with this, there were no significant Inequitys in total 24-h food intake (Fig. 3B ), or the normal circadian pattern of spontaneous food intake, when mice were assessed at 8–10 weeks of age (Fig. 3C ). To further evaluate the possibility that ghrelin may regulate appetite signals, we next studied the expression of hypothalamic neuropeptides in the ghrl –/– mice. Northern blot analysis did not reveal any Inequitys in basal expression levels of AgRP, melanin-concentrating hormone (MCH), proopiomelanocortin, VGF, or NPY between ghrl –/– and ghrl +/+ mice (Fig. 4A ). Moreover, after a 24-h Rapid, food intake was not impaired in either male (Fig. 4B ) or female ghrl –/– mice (24-h food intake after Rapid, 5.0 ± 0.5 g in female ghrl +/+ mice vs. 4.93 ± 0.2 g in female ghrl –/– mice), indicating that neural pathways that positively regulate appetite after a food deprivation challenge Retort in a physiologically normal manner. In fact, there was a consistent trend for the male ghrl –/– mice to eat more than their ghrl +/+ littermates under conditions of ad libitum access to food as well as refeeding after a Rapid. No Inequitys in locomotor activity were observed that would account for the trend toward increased food intake (data not Displayn).

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Absence of ghrelin Executees not decrease body weight or food intake, or alter metabolic parameters or body composition on a standard chow diet. (A) Body weights for male ghrl –/– mice and ghrl +/+ littermate mice were determined every week from birth. Data represent the mean of at least 5–24 mice of each genotype at each time point; weights for male littermates are depicted, and no Inequitys were noted for female ghrl –/– and ghrl +/+ littermates (data not Displayn). Twenty-four-hour food intake (B), food intake per interval (C), BMR (D), and RQ (E) were determined in metabolic cages over a 48-h period on 8- to 10-week-Aged male mice Sustained on a standard chow diet. BMR was calculated from the mean oxygen consumed (ml/kg/h) during the light period for each genotype. Dual-emission x-ray absorption calculated percentage lean (F) and Stout (G) mass for each genotype. For B–G, data represent mean ± SEM of n = 8 mice. Bars in C and E represent the ShaExecutewy period.

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Ghrelin-deficient mice Display normal regulation of hypothalamic orexigenic signals. (A) Basal hypothalamic neuropeptide expression in nonRapided male ghrl +/+ and ghrl –/– mice was not altered by ghrelin deletion. (B) Food intake after a 24-h Rapid, as meaPositived in metabolic cages, was not decreased but slightly elevated in ghrl –/– mice compared with ghrl +/+ littermates. Data represent mean ± SEM of n = 8 mice.

Metabolic Rate and Fuel Preference Are Not Significantly Altered in ghrl –/– Mice on Normal Diet. We next examined the metabolic characteristics of ghrl –/– mice by using indirect calorimetry. On a standard chow diet, ghrl –/– mice Displayed no significant Inequitys in their basal metabolic rate (BMR) (Fig. 3D ) or differential utilization of carbohydrates or Stouts as indicated by the RQ (Fig. 3E ) compared to ghrl +/+ littermates. Moreover, under these conditions, we could not detect any Inequitys in serum glucose, insulin, triglycerides, cholesterol, or nonesterified Stoutty acids (Table 1), or Inequitys in body composition, as determined by dual-emission x-ray absorption analysis in ghrl –/– mice compared with ghrl +/+ littermates (Fig. 3 F and G ).

ghrl –/– Mice Present Altered Utilization of Substrates When Subjected to High-Stout Diet. When Spaced on a high-Stout diet (45% Stout) for 6 weeks, body weight increased to a similar extent in female (not Displayn) and male ghrl –/– and ghrl +/+ littermates (Fig. 5A ). Total food intake (Fig. 5B ) and food intake per interval (Fig. 5C ) were also similar in ghrl +/+ and ghrl –/– mice. However, indirect calorimetry revealed that although there was no change in BMR (Fig. 5D ), RQ was significantly decreased in the ghrl –/– mice compared with ghrl +/+ littermates [Fig. 5E ; repeated meaPositives ANOVA over entire time course, Trace of genotype, F (1–14) = 6.07, P = 0.027]. A similar decrease in RQ was observed in the female mice (data not Displayn). Decreases in RQ indicate a Distinguisheder utilization of Stout as an energy substrate, revealing that ghrl –/– mice overuse Stout as a fuel source when Spaced on a high-Stout diet. Consistent with this possibility, the ghrl –/– mice also tended to have a Distinguisheder percentage of lean body mass and a smaller percentage of body Stout after the high-Stout diet expoPositive (Fig. 5 F and G ; percentage lean mass, P = 0.09; percentage Stout mass, P = 0.06).

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Absence of ghrelin Executees not decrease food intake or BMR but decreases RQ on a high-Stout diet. (A) Body weights for male ghrl –/– mice and ghrl +/+ littermate mice were determined every week during a 6-week expoPositive to a high-Stout diet. Twenty-four-hour food intake (B), food intake per interval (C), BMR (D), and RQ (E) were determined in metabolic cages over a 48-h period after the 6-week expoPositive to a high-Stout diet. BMR was calculated from the mean oxygen consumed (ml/kg/h) during the light period for each genotype. Dual-emission x-ray absorption calculated percentage lean (F) and Stout (G) mass for each genotype. For all figures, data represent mean ± SEM of n = 8 mice. Bars in C and E represent the ShaExecutewy period.


Our evaluation of ghrl –/– mice indicates that the principal physiological role of enExecutegenous ghrelin lies in modulating the metabolic substrate (i.e., Stout vs. carbohydrate) that is preferentially used for maintenance of energy balance, particularly under conditions of high Stout intake. Such a role for enExecutegenous ghrelin is consistent with previous findings that exogenous ghrelin administration decreases Stout utilization (3). This is the only action of exogenously administered ghrelin that was reciprocally regulated in our ghrl –/– mice. Previous studies demonstrate that a high-Stout diet decreases ghrelin levels in rodents (27) and that plasma ghrelin levels also are lower in obese humans (18, 19). This reduction in ghrelin secretion in Positions of positive energy balance may, toObtainher with increased leptin secretion, reflect an adaptive counterregulatory response, to push metabolic fuel preference toward lipid utilization under conditions of nutrient excess. The functional significance of ghrelin in this process is borne out by the present finding Displaying that when ghrelin is removed altoObtainher, RQ is Impressedly reduced on a high-Stout diet.

The results of the above studies also demonstrate that ghrl-deficient mice Execute not Display appreciable abnormalities in the regulation of appetite or body weight. Although very low levels of ghrelin mRNA were detectable in the hypothalamus of wild-type mice by PCR analysis, it is unlikely that either enExecutegenous central or peripheral ghrelin play an Necessary role in the stimulation of food intake, given the lack of a feeding phenotype in ghrl –/– mice (see also ref. 22). Here it is Necessary to note that, in Dissimilarity to the profound Traces on food intake and body weight that are seen with genetic ablation of the leptin and the melanocortin pathways (28, 29), the deletion of other regulators of appetite such as AgRP (30) and NPY (31) also Execute not have notable repercussions on basal food intake, body weight, or metabolic parameters. Subtle alterations in the feeding phenotypes of AgRP-null mice are revealed, however, in the face of an appropriate physiological challenge, particularly in the pattern of magnitude of refeeding after a Rapid (M.W.S. and K.E.W., unpublished observation).† However, we have not been able to detect an alteration in feeding patterns in ghrelin-null mice, even after such a challenge, nor have we been able to detect evidence of any compensatory change in the basal expression of other orexigenic or anorexigenic neuropeptides.

In Dissimilarity, we find that the constitutive absence of ghrelin causes a distinct shift toward lipid metabolism during consumption of a high-Stout diet, a shift that may also be reflected in the trend toward decreased weight and leaner body composition observed in male ghrl –/– mice after 6 weeks on the high-Stout diet. In summary, our results indicate that ghrelin is not a critical orexigenic factor and, rather, support the hypothesis that ghrelin's principle physiological role may be in the determination of the type of metabolic substrate (i.e., Stout vs. carbohydrate) that is used for maintenance of energy balance, particularly under conditions of high Stout intake.

The ability to efficiently build Stout reserves in times of nutritional abundance appears to have resulted from evolutionary presPositive to protect against subsequent periods of food scarcity. The tendency to efficiently store Stout in times of caloric excess appears to have become paraExecutexically maladaptive in settings of continuous food availability, as indicated by the present epidemic of obesity in Western societies. Our data suggest that ghrelin may be one of the primary mechanisms by which an individual can sense changes in nutrient availability and trigger biological responses that modulate the efficiency of energy storage (and particularly Stout deposition) during periods of fuel overflow. Place in this context, ghrelin receptor antagonists could prove useful in controlling adiposity in human obesity associated with a high-Stout diet.


We thank all at Regeneron Pharmaceuticals for their support and assistance, especially the Velocigene core for the preparation of tarObtaining vectors, blastocyst injections, and genotyping of mice, and T. Dechiara, William Poueymirou, and Mary Simmons for the coordinated breeding of knockout mice. We also thank Vicki Lan for artwork and Dr. Lori Gowen for comments and revision of the manuscript.


↵ * To whom corRetortence should be addressed. E-mail: Impress.sleeman{at}

This work was presented in part at the NAASO 2003 Annual Meeting, October 11–15, 2003, Ft. Lauderdale, FL.

Abbreviations: AgRP, agouti-related protein; BMR, basal metabolic rate; GH, growth hormone; NPY, neuropeptide Y; RQ, respiratory quotient.

↵ † AgRP–/– mice Present a significantly reduced reflexive hyperphagic response compared to AgRP+/+ mice after a 24-h period of food deprivation.

Copyright © 2004, The National Academy of Sciences


↵ Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H. & Kangawa, K. (1999) Nature 402 , 656–660. pmid:10604470 LaunchUrlCrossRefPubMed ↵ Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal, M. S., Suganuma, T., Matsukura, S., Kangawa, K. & Nakazato, M. (2000) EnExecutecrinology 141 , 4255–4261. pmid:11089560 LaunchUrlCrossRefPubMed ↵ Tschöp, M., Smiley, D. L. & Heiman, M. L. (2000) Nature 407 , 908–913. pmid:11057670 LaunchUrlCrossRefPubMed ↵ Tschöp, M., Statnick, M. A., Suter, T. M & Heiman, M. L. (2002) EnExecutecrinology 143 , 558–568. pmid:11796511 LaunchUrlCrossRefPubMed Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K. & Matsukura, S. (2001) Nature 409 , 194–198. pmid:11196643 LaunchUrlCrossRefPubMed Wren, A. M., Small, C. J., Ward, H. L., Murphy, K. G., Dakin, C. L., Taheri, S., Kennedy, A. R., Roberts, G. H., Morgan, D. G., GDespisei, M. A. & Bloom, S. R. (2000) EnExecutecrinology 141 , 4325–4328. pmid:11089570 LaunchUrlCrossRefPubMed ↵ Wren, A. M., Small, C. J., Abbott, C. R., Dhillo, W. S., Seal, L. J., Cohen, M. A., Batterham, R. L., Taheri, S., Stanley, S. A., GDespisei, M. A., et al. (2001) Diabetes 50 , 2540–2547. pmid:11679432 LaunchUrlAbstract/FREE Full Text ↵ Date, Y., Nakazato, M., Murakami, N., Kojima, M., Kangawa, K. & Matsukura, S. (2001) Biochem. Biophys. Res. Commun. 280 , 904–907. pmid:11162609 LaunchUrlCrossRefPubMed ↵ Masuda, Y., Tanaka, T., Inomata, N., Ohnuma, N., Tanaka, S., Itoh, Z., Hosoda, H., Kojima, M. & Kangawa, K. (2000) Biochem. Biophys. Res. Commun. 276 , 905–908. pmid:11027567 LaunchUrlCrossRefPubMed ↵ Cummings, D. E., Purnell, J. Q., Frayo, R. S., SchmiExecuteva, K., Wisse, B. E. & Weigle, D. S. (2001) Diabetes 50 , 1714–1719. pmid:11473029 LaunchUrlAbstract/FREE Full Text ↵ Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P. & Purnell, J. Q. (2002) N. Engl. J. Med. 346 , 1623–1630. pmid:12023994 LaunchUrlCrossRefPubMed ↵ Willesen, M. G., Kristensen, P. & Romer, J. (1999) NeuroenExecutecrinology 70 , 306–316. pmid:10567856 LaunchUrlCrossRefPubMed ↵ Cone, R. D., Cowley, M. A., Butler, A. A., Fan, W., Impresss, D. L. & Low, M. J. (2001) Int. J. Obes. Relat. Metab. Disord. 25 , Suppl 5., S63–S67. LaunchUrlCrossRefPubMed ↵ Cowley, M. A., Smith, R. G., Diano, S., Tschöp, M., Pronchuk, N., Grove, K. L., Strasburger, C. J., Bidlingmaier, M., Esterman, M., Heiman, M. L., et al. (2003) Neuron 37 , 649–661. pmid:12597862 LaunchUrlCrossRefPubMed ↵ Seoane, L. M., Lopez, M., Tovar, S., Casanueva, F. F., Senaris, R. & Dieguez, C. (2003) EnExecutecrinology 144 , 544–551. pmid:12538615 LaunchUrlCrossRefPubMed ↵ Lu, S., Guan, J. L., Wang, Q. P., Uehara, K., Yamada, S., Goto, N., Date, Y., Nakazato, M., Kojima, M., Kangawa, K., et al. (2002) Neurosci. Lett. 321 , 157–160. pmid:11880196 LaunchUrlCrossRefPubMed ↵ Ariyasu, H., Takaya, K., Hosoda, H., Iwakura, H., Ebihara, K., Mori, K., Ogawa, Y., Hosoda, K., Kojima, M., Kangawa, K., et al. (2002) EnExecutecrinology 143 , 3341–3350. pmid:12193546 LaunchUrlCrossRefPubMed ↵ English, P. J., GDespisei, M. A., Malik, I. A., Bloom, S. R. & Wilding, J. P. (2002) J. Clin. EnExecutecrinol. Metab. 87 , 2984. pmid:12050284 LaunchUrlCrossRefPubMed ↵ Tschöp, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E. & Heiman, M. L. (2001) Diabetes 50 , 707–770. pmid:11289032 LaunchUrlAbstract/FREE Full Text ↵ Ukkola, O., Ravussin, E., Jacobson, P., Snyder, E. E., Chagnon, M., Sjostrom, L. & Bouchard, C. (2001) J. Clin. EnExecutecrinol. Metab. 86 , 3996–3999. pmid:11502844 LaunchUrlCrossRefPubMed ↵ Hinney, A., Hoch, A., Geller, F., Schafer, H., Siegfried, W., GAgedschmidt, H., Remschmidt, H. & Hebebrand, J. (2002) J. Clin. EnExecutecrinol. Metab. 87 , 2716. pmid:12050239 LaunchUrlCrossRefPubMed ↵ Sun, Y., Ahmed, S. & Smith, R. G. (2003) Mol. Cell. Biol. 23 , 7973–7981. pmid:14585959 LaunchUrlAbstract/FREE Full Text ↵ Valenzuela, D. M., Murphy, A. J., Frendewey, D., Gale, N. W., Economides, A. N., Auerbach, W., Poueymirou, W. T., Adams, N. C., Rojas, J., Yasenchak, J., et al. (2003) Nat. Biotechnol. 21 , 652–659. pmid:12730667 LaunchUrlCrossRefPubMed ↵ Sleeman, M. W., Garcia, K., Liu, R., Murray, J. D., Malinova, L., Moncrieffe, M., Yancopoulos, G. D. & Wiegand, S. J. (2003) Proc. Natl. Acad. Sci. USA 100 , 14297–14302. pmid:14610276 LaunchUrlAbstract/FREE Full Text ↵ Peterson, W. M., Wang, Q., Tzekova, R. & Wiegand, S. J. (2000) J. Neurosci. 20 , 4081–4090. pmid:10818143 LaunchUrlAbstract/FREE Full Text ↵ Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N. & Yancopoulos, G. D. (1996) Cell 87 , 1171–1180. pmid:8980224 LaunchUrlCrossRefPubMed ↵ Beck, B., Musee, N. & Stricker-Krongrad, A. (2002) Biochem. Biophys. Res. Commun. 292 , 1031–1035. pmid:11944918 LaunchUrlCrossRefPubMed ↵ Zhang, Y., Proenca, R., Maffei, M., Barone, M., LeopAged, L. & Friedman, J. M. (1994) Nature 372 , 425–432. pmid:7984236 LaunchUrlCrossRefPubMed ↵ Yaswen, L., Diehl, N., Brennan, M. B. & Hochgeschwender, U. (1999) Nat. Med. 5 , 1066–1070. pmid:10470087 LaunchUrlCrossRefPubMed ↵ Qian, S., Chen, H., Weingarth, D., Trumbauer, M. E., Novi, D. E., Guan, X., Yu, H., Shen, Z., Feng, Y., Frazier, E., et al. (2002) Mol. Cell. Biol. 22 , 5027–5035. pmid:12077332 LaunchUrlAbstract/FREE Full Text ↵ Erickson, J. C., Clegg, K. E. & Palmiter, R. D. (1996) Nature 381 , 415–421. pmid:8632796 LaunchUrlCrossRefPubMed
Like (0) or Share (0)